Invictus MD announce that AB Ventures Inc. has acquired 100 acres for future cannabis cultivation and sale under the ACMPR

Posted on

VANCOUVER, BC, February 9, 2017 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that AB Ventures Inc. (“AB Ventures”), a newly incorporated company formed to develop a second licensed expansion facility through it’s common ownership with AB Laboratories Inc. (“AB Labs”), a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), has acquired 100 acres in Hamilton, Ontario, for cannabis cultivation and sale under the ACMPR.

The land acquisition, worth $1,650,000 CDN, is scheduled to close on May 1, 2017 and will be used for future cannabis cultivation once licensed under the ACMPR. Plans to construct five production facilities on the new land totaling 100,000 square feet will be completed by 2019. AB Labs is licensed for cultivation under the ACMPR and maintains a 16,000 square foot facility located in Hamilton, Ontario.

AB Ventures plans to initially construct 42,000 square feet using the $5.5 million committed from Invictus MD. The entire 100 acres will be available for future expansion. Deloitte, a well-respected consulting company, recently published a survey that suggested the Canadian retail cannabis market would be worth between $4.9 billion and $8.7 billion annually. Additionally, the market for marijuana products and services – including growers, testing labs, lighting, and security systems – would increase that number to between $12.7 billion and $22.6 billion. Once taxes, licensing fees, and weed-related tourism are factored in, the market could be even greater than $22.6 billion. The consulting firm further estimates that satisfying the recreational cannabis market will mean producing 600,000 kilograms of marijuana annually – far more than the existing 38 licensed producers grow for medicinal purposes.

Dan Kriznic, Chairman and CEO of Invictus MD, commented, “This is a tremendous milestone for Invictus-MD and its shareholders. Breaking ground into the ACMPR has always been our intention since inception of our Company in December 2014.” “Once the option to acquire a 100% interest in OptionCo announced on February 7, 2017 is exercised for 150 acres that has already been pre license inspected by Health Canada, along with the previously acquired interest in AB Laboratories, a licensed producer under the ACMPR and the increased expansion plan on 100 acres with AB Ventures, Invictus MD will have significant land holdings for cannabis cultivation in Canada to meet the projected demand. From early on, Invictus MD has viewed acquiring production capacity under the ACMPR as a key driver to increasing shareholder value”, said Kriznic.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,
Dan Kriznic
Chairman & CEO
604-368-6437

Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions of interests in AB Ventures and AB Labs and estimated production capacity, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that all conditions to closing will be satisfied, the proposed acquisitions of AB Ventures and AB Labs will occur as anticipated, that the Company will obtain all requisite approvals of the acquisitions, that AB Ventures will acquire land sufficient to build the proposed cultivation facility and such facility will be successfully built, that AB Ventures will be granted a license to produce the anticipated quantities under the ACMPR and all other required governmental approvals to produce and sell marijuana under the ACMPR will be obtained by AB Ventures and the AB Labs will obtain all approvals required for its proposed production quantities. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that conditions to closing will not be satisfied or that the proposed acquisitions may otherwise not occur as planned, risks related to the timing and receipt of requisite approvals, the risk that AB Ventures will not: acquire land sufficient to build the proposed cultivation facility, successfully build the proposed cultivation facility or obtain a license or any other approvals required to produce the anticipated quantities under the ACMPR, and the risk that AB Labs will not obtain all approvals required for its proposed production quantities. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbour.

Invictus MD Strategies Corp. and Reliq Health Technologies Sign MOU to Collaborate on App for Cannabis Prescribers, Patients and Consumers

Posted on

VANCOUVER, BC, February 8, 2017 – Invictus MD Strategies Corp. (CSE: IMH; OTC: IVITF; FRA: 8IS) (“Invictus MD”) is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with Reliq Health Technologies. (“Reliq”) (TSXV: RHT; OTC: RQHTF) to develop a mobile application for cannabis patients and consumers and their clinical care teams.

Reliq Health, a healthcare technology company focused on developing innovative mobile health and telemedicine solutions, has developed a novel SaaS (software as a service) solution for the community health care market. The solution provides automated remote patient monitoring in the home and secure cloud-based communication, care planning and collaboration for all members of the patient’s circle of care. Reliq’s secure platform allows clinicians to collect comprehensive data on patients’ clinical conditions, medication usage, symptoms, side effects and behaviours – creating a wealth of population health data.

“Studies consistently show that providing patients with the tools they need for self-management of their health conditions produces better health outcomes and reduces healthcare costs. Cannabis is prescribed to treat a wide range of conditions including arthritis, glaucoma, side effects from chemotherapy, chronic pain, multiple sclerosis and post-traumatic stress disorder. Our cannabis app allows patients to track usage and record symptoms specific to their clinical condition, allowing patients and their care providers to determine optimum strain, dosing and mode of administration. Our platform will improve access to care by connecting patients with physicians in their community who have experience with medical marijuana, and supports physician-approved automated prescription refills through participating producers,” said Dr.Lisa Crossley, CEO of Reliq.

Invictus MDs’ Chairman and CEO Dan Kriznic said, “Our wholly owned subsidiary: Poda Technologies Ltd. (“Poda”) is set for a launch in Q2 2017 of its Poda Pod vaporizer product which will provide an effective, reliable and convenient way to vaporize cannabis that is designed to appeal to modern retail and medical consumers.” The Poda Pod vaporizer product, made with medical-grade components, has been designed to connect to users’ smartphones via Bluetooth to provide real time information about dosage, product characteristics, track remaining contents, find vendors nearby, and customize their experience. Agreements are being negotiated to license the PODA products to the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) and licensed Producers in Canada, helping those producers better reach and serve consumers with convenient, refillable devices.

Mr. Kriznic added, “Invictus MD is excited and committed to working collaboratively with Reliq on this innovative mobile application to explore how Reliq’s solution can support Invictus’ commitment to its patients and consumers of cannabis products. Reliq’s technology platform will give Invictus the ability to collect relevant anonymized consumer data such as usage trends, frequency of usage and other relevant insights to improve the overall experience for medical marijuana patients.”

Invictus MD is also pleased to announce that effective February 7, 2017, it has granted a total of 1.2 million options to directors, officers, and consultants of the company at an exercise price of $1.69 per share and an expiry date of February 7, 2022.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) including an investment in a fully licensed facility, AB Laboratories Inc.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,
Dan Kriznic
Chairman & CEO
604-368-6437

Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676

Cautionary Statements Regarding Forward Looking Information
Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.

We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. or Invictus MD Strategies Corp. do not intend, and does not assume any obligation to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, either Reliq Health Technologies Inc. or Invictus MD Strategies Corp. historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.

Invictus MD announces binding LOI to acquire 100% of a Late Stage Applicant under Health Canada’s ACMPR

Posted on

VANCOUVER, BC, February 7, 2017 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that on February 6, 2017 it had entered into a binding letter of intent (“LOI”) for an option to acquire 100% (the “Option”) of the outstanding shares of a Late Stage Applicant (the “OptionCo”) under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) from its current shareholders (the “Vendors”). In early January 2017, OptionCo had its Pre-license inspection from Health Canada and expects to receive a license to cultivate under the ACMPR in short order.

OptionCo has built 60,000 square feet of secured perimeter for its current production facility located on 150 acres (the “Property”), which is expected to have production capacity of up to 6,000 kg per annum. OptionCo has already submitted plans for additional buildings on the Property including a 30,000 square foot facility. Assuming OptionCo receives the requisite regulatory approval to cultivate, OptionCo has future expansion plans on the 150 acre Property to establish itself as a leader in the Canadian cannabis industry.

The Option will be exercisable at the sole option of Invictus MD within 30 days after OptionCo receives its license to cultivate under the ACMPR. The exercise price of the Option will be payable as follows: (i) cash payment of $4 million CDN to the Vendors; (ii) issuing to the Vendors within 10 business days of exercising the Option, 21 million common shares of Invictus MD; and (iii) issuing to the Vendors 3 million warrants with an exercise price of $1.50 per warrant, of which: 1 million warrants will expire in 6 months following the date the Option is exercised; 1 million warrants will expire in 12 months following the date the Option is exercised, and 1 million warrants will expire in 18 months following the date the Option is exercised.

Subject to completion of satisfactory due diligence, Invictus MD intends to enter into a definitive option agreement on or before February 24, 2017.

“Once the option to acquire a 100% interest in OptionCo is exercised, along with the previously acquired interest in AB Laboratories, a licensed producer under the ACMPR, Invictus MD will have significant land holdings for cannabis cultivation in Canada to meet the significant demand. From day one, Invictus MD has viewed acquiring production capacity under the ACMPR as a key driver to increasing shareholder value”, said Dan Kriznic, Chairman and CEO of Invictus MD. According to a recent report from the consulting firm Deloitte “Recreational Marijuana – Insights and Opportunities”, the Canadian retail cannabis market is projected to be between $4.9 billion and $8.7 billion annually. In that same report, Deloitte further estimates that satisfying the recreational cannabis market will mean producing 600,000 kilograms of marijuana annually – far more than the existing licensed producers under the ACMPR grow for medicinal purposes.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including an investment in a fully licensed facility, AB Laboratories Inc.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,
Dan Kriznic
Chairman & CEO
604-368-6437

Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the definitive agreement with OptionCo, the proposed exercise of the Option and acquisition of OptionCo, the potential production capacity of the Property and OptionCo’s expectations to receive a a cultivation license under the ACMPR are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be satisfied with its due diligence on OptionCo, that the Company will obtain stock exchange and all other applicable regulatory approvals of the proposed Option, that the Company will raise sufficient funds to exercise the Option, that OptionCo will abide by and pass all regulations and inspections required under the ACMPR and be issued a cultivation license and that Health Canada will approve the required facilities to meet the anticipated production capacity of the Property. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed exercise of the Option may not occur as planned; the timing and receipt of requisite approvals and failure of the Company to raise sufficient funds to exercise the Option; OptionCo will not abide by and pass all regulations and inspections required to be issued a cultivation license under the ACMPR and Health Canada will not approve the required facilities to meet the anticipated production capacity of the Property. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

Invictus MD Strategies Corp. CEO’s Update to Shareholders

Posted on

VANCOUVER, BC, January 26, 2017 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) Chairman and CEO Dan Kriznic is pleased to provide this update to it’s shareholders.

2016 was a transformational year for Invictus MD. The Company’s majority interest in Future Harvest Development Ltd. (“FHD”), initially purchased in February 2015, has performed exceptionally well. FHD produced record sales in 2016 as the burgeoning market for commercial hydroponics products continued to show an appetite for FHD’s unique lines of nutrients and equipment. Despite 50% year over year sales growth in 2016, the company is confident that FHD’s best growth is still ahead. The timely acquisition of a bottling line and exceptional performance and leadership of key hires are leading an expansion into the fertilization sector, where key growth opportunities have been identified. Under the direction of Chris Pearson and newly hired research consultant from the University of British Colombia Dr. Paul Shipley, and head bioengineer Justin Pearson, FHD’s Plant Life Products and Holland Secret brands are successfully competing for and winning fertilizer market share. The fertilizer brands, along with the continuing success of companion metering product Grow Boss is earning the company a significant and growing position in the commercial hydroponics market.

The sale of FHD’s Sunblaster lighting line for $4.8 million in cash allowed the company the opportunity to issue a $0.07/ share dividend in December 2016 to Invictus MD shareholders for a total of approximately $1 million. The company remains committed to identifying undervalued cannabis industry assets and delivering that value to the shareholders.

Invictus MD expanded its portfolio of cultivation assets in 2016 by acquiring interests in Hamilton, ON based AB Laboratories Inc., a licensed producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) and more recently signed a binding letter of intent to acquire 100 percent of PlanC BioPharm Inc., a late stage applicant in active final review stage with Health Canada for a license under the ACMPR. The acquisition strategy is being conducted under the consultation of head horticulturist Philip Hague, and industry advisors Cannera Consultants. Philip Hague has designed and built out over 1 million square feet of licensed facilities in the US. The Company has made agreements to acquire interests in two other cultivation licenses in the US through the issuance of a combination of stock and cash over time at their sole option. A similar staged acquisition agreement was made in 2016 affording the Company the option to purchase a 49% interest in Zenalytic Laboratories (“Zen Labs), a Kelowna, BC based cannabis testing facility. Zen Labs has a revenue generating analytical testing laboratory, and expects to receive a Section 56 Class Exemption Dealer’s license from Health Canada, that will allow it to make efficient use of its 1500 square foot Kelowna facility.

The Company has invested in these complementary assets in order to take advantage of growth opportunities at both the cultivation and processing levels. Invictus MD continues to be interested in business assets at all stages of the cannabis business with a primary focus to be a leading cannabis cultivator in Canada under the ACMPR.

In 2017,, Invictus MD plans to expand both its individual cultivation assets and its wider cultivation portfolio. The team expects to have combined 154 acres of AMPR licensed cultivation by the end of 2017. The expansion plan forecasts 45,000 kilograms of high quality cannabis production by 2020 from Canadian assets alone. Invictus MDs’ Canadian production targets have been set in accordance with market forecasts provided by Deloitte, who estimates that the fulfillment of total Canadian retail marijuana demand “would require producing over 600,000 kilograms of marijuana annually…”

Invictus MDs’ wholly owned 2016 venture into consumer cannabis devices; Poda Technologies Ltd. (“Poda”) is set for an exciting launch in Q2 2017. Poda will roll out an effective, reliable and convenient way to vaporize cannabis that is designed to appeal to modern retail and medical consumers. The Poda Pod vaporizer product has been designed to connect to users’ smartphones via bluetooth, providing real time information about dosage, product characteristics, supply, and availability. Agreements are being negotiated to license the PODA products to ACMPR licensed producers in Canada, helping those producers better reach and serve consumers with convenient, refillable devices. Company research has identified enormous potential in processed consumer cannabis products, and management is looking forward to acquiring and developing proven consumer brands in the cannabis space going forward.

About Invictus MD Strategies Corp.
Invictus MD’s primary vision is to become a leading producer in Canada under the ACMPR in order to meet future demand targets. We provide not only capital to meet this objective but also years of management experience from a team that has been successful in all facets of business, from establishing start-ups to running large international organizations. The fundamental core of our operations centers on the vast opportunities within the cannabis industry.

Invictus MD works in partnership with management teams to increase shareholder value through business planning and process integration, developing and executing growth strategies, leveraging our experience and relationships, and structuring and deploying the proper capital to support long-term growth. Our prudent approach to both investing in and developing successful companies ensures successful execution of the business plan in both times of economic expansion and contraction.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,
Dan Kriznic
Chairman & CEO
604-368-6437

Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, that the Company will obtain all requisite approvals of the spin-out transaction, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed spin-out may not occur as planned; the timing and receipt requisite approvals. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbour.

Invictus MD Strategies Corp. Announces the Appointment of Larry Heinzlmeir as Vice President, Marketing and Communications

Posted on

VANCOUVER, BC, January 24, 2017 – INVICTUS MD STRATEGIES CORP. (Invictus MD) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that Larry Heinzlmeir has joined the company as Vice President of Marketing and Communication, reporting to Chairman and CEO Dan Kriznic.

Heinzlmeir is an authority on digital marketing, online platforms and brand strategy. He joins Invictus MD with more than 25 years of executive level experience in sales and marketing, driving substantial growth for several of the largest publicly traded companies in the for-profit higher education sector, including DeVry and EDMC.

“Larry is a strategic appointment for us as we focus our resources on acquiring Licensed Producers in Canada and providing ancillary products in the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), cannabis market, said Kriznic. “He encompasses everything we are looking for in a senior marketing and communications leader and I’m thrilled to have him on our team.”

Before joining Invictus MD, Heinzlmeir was Vice President of Marketing and CMO of a large privately held, growth-oriented organization, where he managed an annual marketing budget in excess of $24m and achieved an eight-fold increase in revenue.

“I am profoundly honored to join Invictus MD,” said Heinzlmier. “I have enormous respect for the team and hope I can contribute to the company’s continued success and leadership.”

About Invictus MD Strategies Corp.
Invictus MD targets cannabis companies with proven brands, strong customer focus, and significant growth potential. We provide not only capital to meet these objectives but also years of management experience from a team that has been successful in all facets of business, from establishing start-ups to running large international organizations. The fundamental core of our operations centers on the vast opportunities within fragmented industries.

Invictus MD works in partnership with management teams to increase shareholder value through business planning and process integration, developing and executing growth strategies, leveraging our experience and relationships, and structuring and deploying the proper capital to support long-term growth. Our prudent approach to both investing in and developing successful companies ensures successful execution of the business plan in both times of economic expansion and contraction.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,

Dan Kriznic
Chairman & CEO
604.368.6437

Larry A Heinzlmeir
Vice President, Marketing & Communications
604.537.8676

Invictus MD announces binding LOI to acquire PlanC BioPharm Inc., a Late Stage Applicant under Health Canada’s ACMPR

Posted on

VANCOUVER, BC, January 17, 2017 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that it has entered into a binding letter of intent (“LOI”) to acquire 100% of PlanC BioPharm Inc. (“PlanC”), a Late Stage Applicant under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”).

PlanC is currently in active final review stage with Health Canada for an application that was submitted in 2014 based on a proposed initial 30,000 square foot, state-of-the-art, medicinal cannabis production and processing facility located on 5 acres just outside Salmo, British Columbia (the “Property”). Invictus MD will issue to the PlanC shareholders $100,000 in cash and 50,000 common shares to a maximum value for such common shares of $70,000 as consideration for entering into the LOI. In addition, Invictus MD will pay $100,000 in cash and 100,000 in common shares to a maximum value for such common shares of $175,000 as consideration for signing a definitive agreement (“the Definitive Agreement”). The Definitive Agreement will require the following common share issuances to the current shareholders of PlanC upon the occurrence of the following milestones up to a maximum aggregate value for such common shares of $10 million: (i) 200,000 common shares to a maximum value of $400,000 on the closing of the sale of PlanC’s shares to Invictus MD; (ii) 300,000 common shares to a maximum value of $600,000 upon PlanC receiving an affirmation email from Health Canada; (iii) 500,000 common shares to a maximum value of $1,000,000 upon the completion of pre-licensing inspection; and (iv) 5,000,000 common shares to a maximum value of $8,000,000 upon PlanC’s receipt of a cultivation license under the ACMPR. In connection with each such issuance of Invictus common shares, the value of each Invictus common share value will be the closing share price of the Company immediately prior to the date the milestone is achieved.

Invictus MD is required to contribute $8 million to be held in escrow for the benefit of PlanC (the “Escrow Monies”) within 90 days of signing the Definitive Agreement. The Escrow Monies will be used to exercise an option to acquire the Property, construct the 30,000 square foot facility and for general working capital purposes. PlanC also has an option to purchase a 49-acre parcel of land immediately adjacent to its proposed facility, thereby giving PlanC a secure basis from which to plan future expansion and, assuming PlanC receives the requisite regulatory approval to produce its forecasted capacity, to accommodate cannabis production of up to 20,000 kg per year, establishing itself as a leader in the cannabis industry.

Dan Kriznic, CEO of Invictus MD, stated, “This acquisition allows us to continue with our strategy of increasing cannabis production capacity under the ACMPR to meet the significant demand. Invictus MD also acquired 33.33% of AB Laboratories Inc., a Licensed Producer under the ACMPR in December 2016”. According to the recent report “Recreational Marijuana – Insights and Opportunities” by the consulting firm Deloitte, the Canadian retail cannabis market could be worth between $4.9 billion and $8.7 billion annually. In that same report, the consulting firm further estimates that satisfying the recreational cannabis market will mean producing 600,000 kilograms of marijuana annually – far more than the existing 38 licensed producers grow for medicinal purposes.

About Invictus MD Strategies Corp.

Invictus MD targets cannabis companies with proven brands, strong customer focus, and significant growth potential. We provide not only capital to meet these objectives but also years of management experience from a team that has been successful in all facets of business, from establishing start-ups to running large international organizations. The fundamental core of our operations centers on the vast opportunities within fragmented industries.

Invictus MD works in partnership with management teams to increase shareholder value through business planning and process integration, developing and executing growth strategies, leveraging our experience and relationships, and structuring and deploying the proper capital to support long-term growth. Our prudent approach to both investing in and developing successful companies ensures successful execution of the business plan in both times of economic expansion and contraction.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,

Dan Kriznic
Chairman & CEO
604.368.6437

Larry A Heinzlmeir
Vice President, Marketing & Communications
604.537.8676

Cautionary Note Regarding Forward-Looking Statements: This release includes
certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisition of PlanC, the Company raising the Escrow Monies through an equity financing and Health Canada granting PlanC a cultivation license under the ACMPR are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the proposed acquisition of PlanC as anticipated, that the Company will raise sufficient funds to pay the Escrow Monies, that the Company will obtain all other requisite approvals for the acquisition and that PlanC will abide by and pass all regulations and inspections required under the ACMPR and be issued a cultivation license. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure of the Company to raise sufficient funds to pay the Escrow Monies; and PlanC will not abide by and pass all regulations and inspections required to be issued a cultivation license under the ACMPR. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

Invictus MD closes acquisition of shares in ACMPR Licensed Producer AB Laboratories Inc.

Posted on

VANCOUVER, BC, December 29, 2016 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that it has closed the acquisition of 33.33% of the shares of AB Laboratories Inc. and the initial acquisition of shares of AB Ventures Inc., as previously announced on December 23, 2016.

Dan Kriznic, CEO of Invictus MD, commented, “This investment in AB Laboratories Inc. and AB Ventures Inc. solidifies Invictus MD as a major player on the forefront of the cannabis industry.”

AB Laboratories Inc. is licensed for cultivation under the ACMPR and maintains a 16,000 square foot facility located in Hamilton, Ontario. The Company paid CAD$5,000,000 and issued 2.4 million common shares to the vendor at closing, with a further CAD$2,000,000 in cash due in 90 days.

AB Ventures Inc. is a newly incorporated company that plans to acquire and develop 100 acres in Hamilton, Ontario for cannabis cultivation and sale under the ACMPR. Invictus MD has committed $7.5 million to fund the costs of licensing approval under the ACMPR, acquiring land and constructing the cultivation facility, in exchange for a 33.33% interest in AB Ventures. The Company advanced an initial $2 million at closing into escrow to be deployed primarily for the purchase of the land.

About Invictus MD Strategies Corp.

Invictus MD targets cannabis companies with proven brands, strong customer focus, and significant growth potential. We provide not only capital to meet these objectives but also years of management experience from a team that has been successful in all facets of business, from establishing start-ups to running large international organizations. The fundamental core of our operations centers on the vast opportunities within fragmented industries.

Invictus MD works in partnership with management teams to increase shareholder value through business planning and process integration, developing and executing growth strategies, leveraging our experience and relationships, and structuring and deploying the proper capital to support long-term growth. Our prudent approach to both investing in and developing successful companies ensures successful execution of the business plan in both times of economic expansion and contraction.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,

Dan Kriznic
Chairman & CEO
604.368.6437

Larry A Heinzlmeir
Vice President, Marketing & Communications
604.537.8676

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding plans and objectives, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that AB Ventures will acquire land sufficient to build a cultivation facility and such facility will be successfully built and that all other required governmental approvals to produce and sell marijuana under the ACMPR will be obtained by AB Ventures. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, that the acquisition of shares may otherwise not occur as planned, the risk that AB Ventures will not: acquire land sufficient to successfully build a cultivation facility or obtain a license or any other approvals required to produce and sell marijuana under the ACMPR. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbour.

Invictus MD closes acquisition of ACMPR Licensed Producer AB Laboratories Inc.

Posted on

VANCOUVER, BC, December 23, 2016 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that it has signed the definitive agreement to acquire 33.33% of AB Laboratories Inc. (“AB Labs”), a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), and up to 33.33% of AB Ventures Inc. (“AB Ventures”), a newly incorporated company formed to develop a second licensed expansion facility.

Under the terms of the agreement Invictus MD will acquire 33.33% of AB Labs, for consideration of CAD$5,000,000 in cash and 2.4 million common shares of Invictus MD on closing and CAD$2,000,000 in cash 90 days after closing. AB Labs is licensed for cultivation under the ACMPR and maintains a 16,000 square foot facility located in Hamilton, Ontario. Invictus MD will have the right of first refusal to arrange any initial public offering, reverse take-over or other going public transaction of AB Labs or AB Ventures following closing. Closing is expected to take place by December 29, 2016.

AB Ventures plans to acquire and develop 100 acres in Hamilton, Ontario for cannabis cultivation and sale under the ACMPR. Invictus MD has committed $7.5 million to fund for the costs of licensing approval under the ACMPR, acquiring land and constructing the cultivation facility, in exchange for a 33.33% interest in AB Ventures. AB Ventures is currently in negotiation to acquire a suitable property and has plans to initially construct a 21,000 square foot facility, which would position the company to become one of the top tier Licensed Producers in Canada. Considering the anticipated size of AB Ventures’ proposed land acquisition and facility and assuming AB Ventures obtains a license to produce the quantity forecasted for the proposed facility, the combined production capacity of both AB Labs and AB Ventures is expected to exceed 20,000 kilograms in 2019. Deloitte, a well-respected consulting company, recently published a survey that suggested the Canadian retail cannabis market would be worth between $4.9 billion and $8.7 billion annually. Additionally the market for marijuana products and services – including growers, testing labs, lighting, and security systems – would increase that number to between $12.7 billion and $22.6 billion. Once taxes, licensing fees, and weed-related tourism are factored in, the market could even be greater than $22.6 billion. The consulting firm further estimates that satisfying the recreational cannabis market will mean producing 600,000 kilograms of marijuana annually – far more than the existing 36 licensed producers grow for medicinal purposes.

Dan Kriznic, CEO of Invictus MD, commented, “This is a tremendous milestone for Invictus-MD and its shareholders. Breaking ground into the ACMPR has always been our intention since inception of our Company in December 2014. Partnering with the right team has been the most important criteria. After meeting, discussing, and conducting our due diligence on over 5 Licensed Producers, we are pleased with our partnership with AB Labs and AB Ventures. When both parties met, we both knew that this would be a great fit immediately.”

About Invictus MD Strategies Corp.

Invictus MD targets cannabis companies with proven brands, strong customer focus, and significant growth potential. We provide not only capital to meet these objectives but also years of management experience from a team that has been successful in all facets of business, from establishing start-ups to running large international organizations. The fundamental core of our operations centers on the vast opportunities within fragmented industries.

Invictus MD works in partnership with management teams to increase shareholder value through business planning and process integration, developing and executing growth strategies, leveraging our experience and relationships, and structuring and deploying the proper capital to support long-term growth. Our prudent approach to both investing in and developing successful companies ensures successful execution of the business plan in both times of economic expansion and contraction.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,

Dan Kriznic
Chairman & CEO
604.368.6437

Larry A Heinzlmeir
Vice President, Marketing & Communications
604.537.8676

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions of interests in AB Ventures and AB Labs and estimated production capacity, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that all conditions to closing will be satisfied, the proposed acquisitions of AB Ventures and AB Labs will occur as anticipated, that the Company will obtain all requisite approvals of the acquisitions, that AB Ventures will acquire land sufficient to build the proposed cultivation facility and such facility will be successfully built, that AB Ventures will be granted a license to produce the anticipated quantities under the ACMPR and all other required governmental approvals to produce and sell marijuana under the ACMPR will be obtained by AB Ventures and the AB Labs will obtain all approvals required for its proposed production quantities. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that conditions to closing will not be satisfied or that the proposed acquisitions may otherwise not occur as planned, risks related to the timing and receipt of requisite approvals, the risk that AB Ventures will not: acquire land sufficient to build the proposed cultivation facility, successfully build the proposed cultivation facility or obtain a license or any other approvals required to produce the anticipated quantities under the ACMPR, and the risk that AB Labs will not obtain all approvals required for its proposed production quantities. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbour.

Invictus MD hires top tier cannabis consultants and Chief Science Officer for North America wide conquest

Posted on

Vancouver, BC, December 12, 2016 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce it has entered into a consulting agreement with Cannera Consultants (“Cannera”) and has enlisted Phillip Hague to undertake the role of Chief Science Officer and Head of Horticulture.

Cannera, a division of the GreenTec Bio-Pharmaceuticals Group has entered into an agreement with Invictus MD to oversee all Canadian assets and acquisitions within the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), and provide assistance with certain U.S. acquisitions. Cannera, which was the intermediary party in bridging Invictus MD with AB Laboratories Inc, has played an integral role in negotiating and executing the Binding Letter of Intent for this Licensed Producer, signed by both parties on November 23rd, 2016. Cannera’s vast rolodex and expertise in the industry will play a pivotal role in Invictus MD’s aggressive North America wide conquest.

Cannera currently operates and manages all cultivation duties at an ACMPR Licensed Producer in British Columbia, which was one of the original 13 Licensed Producers. As of January 2nd, 2017, Cannera will assume the role of “Head of ACMPR Business Development” & “Head of ACMPR Operations” for Invictus MD. Cannera’s Senior Consultant sits on the advisory board of Doventi Capital Inc (a legal Cannabis Private Equity Fund), and is the Senior Operations Manager of GreenTec Nevada Holdings, which Invictus MD has secured an Option to purchase up to 60% of.

Phillip Hague will assume the role of Head of Horticulture for the United States. Mr. Hague is currently managing a State licensed cultivation facility in Chicago Illinois that is 120,000 square feet, and a New York state licensed facility that is 320,000 square feet. Mr. Hauge comes from a traditional large-scale commercial controlled agriculture environment, and brings a lifetime of passion and experience into the industry. He is recognized as one of the industry’s most sought after consultants. He has designed, built, staffed and maintained over 1,000,000 square foot of indoor cannabis cultivation and more than 20 acres of greenhouse facilities.

After transitioning from traditional horticulture into the cannabis space Phillip quickly built some of the most recognizable and successful brands in the cannabis industry, gaining the respect and interest of his peers and the media. Winner of multiple awards including several prestigious Cannabis Cups, Phillip has been featured in numerous articles and news programs on the cannabis industry including National Geographic’s “the science of weed”, 60 minutes “The Marijuana Effect”, Rolling Stone’s “too high to fail”, Chicago Sun Time’s “A New Crop”, as well as multiple industry publications and news magazines such as CNN, MSNBC, Wall Street Journal and many others.

 

Dan Kriznic, CEO commented “These are fundamental additions to Invictus MD’s management and growth team, both Phillip and Cannera are highly sought after consultants and bring a track record of proven results and success. With Canada’s task force developing the legal framework behind recreational legalization and the recent U.S. states that have voted in favour of legalizing cannabis for medical or recreational, we are pleased more than ever to aggressively focus on building a cultivation platform across North America, as well as Future Harvest’s brand recognition globally. 2017 will be a victorious year for Invictus MD and its shareholders as we navigate across the North American legal cannabis sector and its ancillary support verticals”

About Invictus MD Strategies Corp.

Invictus MD targets cannabis companies with proven brands, strong customer focus, and significant growth potential. We not only provide capital to meet these objectives but also years of management experience from a team that has been successful in all facets of business from start-ups to running large international organizations. The fundamental core of our operations is centered on the vast opportunities within fragmented industries in the cannabis space.

Invictus MD works in partnership with management teams to increase shareholder value through business planning and process integration, developing and executing growth strategies, leveraging our experience and relationships, and structuring and deploying the proper capital to support long-term growth. Our prudent approach to both investing in and developing successful companies ensures successful execution of the business plan in both times of economic expansion and contraction.

For more information please visit www.invictus-md.com.

On Behalf of the Board,

Dan Kriznic

Chairman & CEO

604-368-6437

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed spin-out of Future Harvest, are forward-looking statements and contain forward-looking information.  Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”.  Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the proposed spin-out of Future Harvest will occur as anticipated, that the Company will obtain all requisite approvals of the spin-out transaction, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed spin-out may not occur as planned; the timing and receipt requisite approvals. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.  Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information.  Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws.  We seek safe harbour.

Invictus MD announces binding Letter of Intent to acquire 20% Washington i502 Cultivation & Processing License

Posted on

Vancouver, BC, December 7, 2016 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce it has entered into a binding Letter of Intent to acquire a Tier 2 State of Washington Cultivation and Processing License (”The Operation”).

Invictus MD will pay $1,000,000 USD cash by way of a convertible debenture to Cannera Equipment Leasing (“CEL”). CEL has committed up to $1,000,000 USD by way of equipment financing and tenant upgrades to the Licensed facility which is currently in final stages of construction, and will have the capacity to produce 2,500kg annually.

Upon final licensing approval by the Washington State Liquor and Cannabis Board (“WLCB”), Invictus MD will pay $2,000,000 USD and issue 800,000 shares with a maximum value of $2,000,000 USD to CEL to secure its option to execute, assign or transfer 20% equity. The operation has a strategic partnership with a renowned genetics and extracts brand located in California, with an established foothold in the California, Nevada and Washington market.

The details of the Binding Letter of Intent will also grant Invictus MD the Right of First Refusal on; all future capital raises, any shares offered for sale, and listing on any publicly traded exchange.

Dan Kriznic, CEO commented “This is yet another strategic acquisition for Invictus MD. The operations team has an established foothold within the California, Washington and Nevada markets. With this placeholder acquisition, Invictus MD will

be well positioned to establish and execute operations in Washington and continue to build Future Harvest’s brand through its i502 partners.”

About Invictus MD Strategies Corp.

Invictus MD targets cannabis companies with proven brands, strong customer focus, and significant growth potential. We not only provide capital to meet these objectives but also years of management experience from a team that has been successful in all facets of business from start-ups to running large international organizations. The fundamental core of our operations is centered on the vast opportunities within fragmented industries in the cannabis space.

Invictus MD works in partnership with management teams to increase shareholder value through business planning and process integration, developing and executing growth strategies, leveraging our experience and relationships, and structuring and deploying the proper capital to support long-term growth. Our prudent approach to both investing in and developing successful companies ensures successful execution of the business plan in both times of economic expansion and contraction.

For more information please visit www.invictus-md.com.

On Behalf of the Board,

Dan Kriznic

Chairman & CEO

604-368-6437

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed spin-out of Future Harvest, are forward-looking statements and contain forward-looking information.  Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”.  Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the proposed spin-out of Future Harvest will occur as anticipated, that the Company will obtain all requisite approvals of the spin-out transaction, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed spin-out may not occur as planned; the timing and receipt requisite approvals. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.  Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information.  Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws.  We seek safe harbour.